From: Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
Drug target | Drugs in trial | Study in population | Outcomes reported | Reference |
---|---|---|---|---|
ACC inhibitor | Firsocostat | NASH | ↓ Hepatic lipid content, ↓ fibrosis | [156] |
PF-05221304 | NASH | ↓ Steatosis, ↓ ALT/AST, ↑ Hypertriglyceridema | [157] | |
FASN inhibitor | TVB 2640 | NASH | ↓Hepatic lipid content, ↓ ALT, ↓ LDL-C, ↓ Fibrosis | [158] |
SCD1 inhibitor | Aramchol | NASH | ↓ Hepatic lipid content, ↓ ALT, ↓ Fibrosis | |
DGAT inhibitor | PF-06865571 | NASH | ↓ Hepatic lipid content | [163] |
MGAT2 inhibitor | BMS-963,272 | NASH (Cynomolgus monkeys) | ↓ Inflammation, ↓ Fibrosis | [168] |
Hypolipidemic Drugs | Atorvastatin | Hypercholesterolemia with hepatic damage | ↓ Hepatic lipid content, ↓ Hepatic enzymes | [171] |
Rosuvastatin | NASH | ↓ ALT/AST, ↓ Fibrosis | [218] | |
FGF21 analogue | Pegbelfermin | NASH | ↓ Hepatic lipid content, ↑ Insulin sensitivity | [177] |
B1344 | NAFLD (Cynomolgus monkeys) | ↓ Hepatic lipid content, ↓ Steatosis, ↓Inflammation, ↓ Fibrosis | [179] | |
PPAR agonist | Pioglitazone | NASH | ↓Hepatic lipid content, ↓ ALT/AST | [184] |
Elafibranor | Abdominally obese insulin-resistant males | ↓ ALT/AST, ↑ Insulin sensitivity | [188] | |
Saroglitazar | NASH | ↓ Hepatic lipid content | [219] | |
Lanifibranor | NASH | ↓ Hepatic lipid content, ↓Inflammation, ↓ Fibrosis | [189] | |
SGLT-2 inhibitor | Dapagliflozin | Type 2 diabetes | ↓ Hepatic lipid content | [192] |
Empagliflozin | NAFLD | ↓ Hepatic lipid content, ↓ ALT/AST | [191] | |
GLP-1 modulator | Liraglutide | NASH | ↑ Insulin sensitivity, ↓ NAS score, ↓ ALT/AST | [199] |
Exenatide | NASH | ↓Hepatic lipid content, ↓ ALT/AST, ↓ Inflammation | [196] | |
DPP4 inhibitor | Sitagliptin | NASH | No effect on NAS score | [206] |
KHK inhibitor | PF-06835919 | NASH | ↓ Hepatic lipid content | [209] |
Probiotics | Â | NAFLD | No effect on hepatic lipid content and inflammation | [220] |
Fecal transplantation | Â | NAFLD | No effect on hepatic lipid content and inflammation | [210] |
FXR agonist | Obeticholic acid | NASH | ↓ Steatosis, ↓ Inflammation, ↓ Fibrosis | [212] |
Cilofexor | NASH | ↓ Hepatic lipid content, ↓ Steatosis, ↓ Primary BAs | [213] | |
EDP-305 | NASH | ↓ Hepatic lipid content, ↓ ALT | [214] | |
TRβ agonist | Resmetirom | NASH | ↓ Hepatic lipid content, ↓ ALT/AST | [215] |
FGF19 analogue | Aldafermin | NASH | ↓ Hepatic lipid content, ↓ ALT/AST | [217] |